Clinical significance of runt-related transcription factor 1 polymorphism in prostate cancer

BJU International

Volumn 107, Issue 3, 2011, Pages 486-492

  Huang, Shu Pin ^a,b,c   Lan, Yu Hsuan ^d   Lu, Te Ling ^f   Pao, Jiunn Bey ^h   Chang, Ta Yuan ^e   Lee, Hong Zin ^d   Yang, Wen Hui ^e   Hsieh, Chi Jeng ^h   Chen, Lu Min ^g   Huang, Li Chia ^g   Ting, Wen Chien ^g   Bao, Bo Ying ^d,g  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e Department of Occupational Safety and Health ^*  (China)

^f CHINA MEDICAL UNIVERSITY   (China)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

lymph node metastasis; prostate cancer; runt related transcription factor 1; single nucleotide polymorphism

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HOMOZYGOSITY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RUNT RELATED TRANSCRIPTION FACTOR 1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALLELES; CORE BINDING FACTOR ALPHA 2 SUBUNIT; EPIDEMIOLOGIC METHODS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 79251565549     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09512.x     Document Type: Article

References (27)

1. Westendorf JJ, Hiebert SW,. Mammalian runt-domain proteins and their roles in hematopoiesis, osteogenesis, and leukemia. J Cell Biochem 1999; 32-33 (Suppl.): 51-8
2. Blyth K, Cameron ER, Neil JC,. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005; 5: 376-87
3. Look AT,. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059-64
4. Fowler M, Borazanci E, McGhee L, et al. RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region. J Cell Biochem 2006; 97: 1-17
5. Lutterbach B, Westendorf JJ, Linggi B, Isaac S, Seto E, Hiebert SW,. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem 2000; 275: 651-6
6. Pratap J, Lian JB, Javed A, et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006; 25: 589-600
7. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39: 645-9
8. Huang SP, Chou YH, Chang WS, et al. Androgen receptor gene polymorphism and prostate cancer in Taiwan. J Formos Med Assoc 2003; 102: 680-6
9. Huang SP, Chou YH, Wayne Chang WS, et al. Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett 2004; 207: 69-77
10. Huang SP, Huang CY, Wang JS, et al. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy. Clin Cancer Res 2007; 13: 6632-8
11. Huang SP, Huang CY, Wu WJ, et al. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int J Cancer 2006; 119: 1902-7
12. Huang SP, Wu WJ, Chang WS, et al. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 2217-24
13. Gleason DF, Mellinger GT,. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 58-64
14. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-9
15. Huang SP, Huang LC, Ting WC, et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2009; 18: 3068-74
16. Fleming ID, Cooper JS, Henson DE, et al., eds. AJCC Cancer Staging Manual, 5th edn. American Joint Committee on Cancer. Philadelphia: Lippincott-Raven, 1997
17. Freedland SJ, Sutter ME, Dorey F, Aronson WJ,. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003; 61: 365-9
18. Daneshmand S, Quek ML, Stein JP, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004; 172: 2252-5
19. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer 2004; 101: 2371-490
20. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ,. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66
21. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-61
22. Yuan HY, Chiou JJ, Tseng WH, et al. FASTSNP: An always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res 2006; 34: W635-41
23. Bibikova M, Chudin E, Arsanjani A, et al. Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics 2007; 89: 666-72
24. McCabe CD, Spyropoulos DD, Martin D, Moreno CS,. Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer. Cancer Res 2008; 68: 1988-96
25. Banach-Petrosky W, Jessen WJ, Ouyang X, et al. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res 2007; 67: 9089-96
26. Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood 1999; 93: 1817-24
27. Tokuhiro S, Yamada R, Chang X, et al. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 2003; 35: 341-8